Nuwellis, Inc. reported its financial results for the first quarter of 2025, showing a revenue of $1.9 million, which marks a 3% increase compared to the same period in 2024. This growth was attributed to a 4% rise in consumables utilization and higher U.S. console sales, partially offset by a decline in international sales. However, the company's gross margin decreased to 56.0% from 64.1% in the prior-year quarter, primarily due to unfavorable manufacturing variances and lower fixed overhead absorption. The net loss attributable to common shareholders was $3.0 million, compared to a net loss of $3.8 million in the same period in 2024. Operating loss improved to $3.1 million, down from $4.7 million in the previous year's first quarter. Total operating expenses for the quarter were reduced by 31% to $4.1 million, driven by a significant decrease in selling, general, and administrative expenses as well as research and development expenses. Nuwellis highlighted strategic advancements, including growth in customer categories and strengthened foundations for Aquadex therapy adoption. The company is well-positioned to expand both inpatient and outpatient environments in 2025, with higher CMS reimbursement and strong pediatric performance contributing to its optimism. As of March 31, 2025, Nuwellis held $2.6 million in cash and cash equivalents and remained debt-free.